Published in Biotech Law Weekly, April 7th, 2006
It is the largest venture capital raise in the Minnesota medical device industry in the last 20 months. Prism Venture Partners led the round and substantial commitments were received from the existing investors and Tullis-Dickerson, a new investor.
With this capital, the company will complete enrollment in the Protect AF clinical trial.
Atritech's Watchman device is designed to keep harmful sized blood clots from entering a patient's blood stream, potentially causing a stroke. Patients with atrial...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.